organization · Reporting owner
Fortress Biotech, Inc.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | 10% owner | January 02, 2026 | January 06, 2026 |
| Journey Medical CorpDERM · Entity 6273 | 10% owner | May 12, 2022 | May 31, 2024 |
| MUSTANG BIO, INC.MBIO · Entity 8350 | 10% owner | January 02, 2026 | January 05, 2026 |
| NATIONAL HOLDINGS CORPNHLD · Entity 142239 | 10% owner | September 12, 2016 | September 22, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 439,733 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 111,209 · Balance 439,733 F1: The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 111,209 shares were granted by the Issuer to the reporting Person for the 2025 annual dividend. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 111,209 shares were granted by the Issuer to the reporting Person for the 2025 annual dividend.
Journey Medical Corp
Report date May 12, 2022 · Filed May 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 3,860,467 |
Ending reported balance
After 2023-05-12 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2022-05-12 · Other · Disposed 50,000 · Balance 4,060,467 F1: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Row 2 · 2022-08-12 · Other · Disposed 50,000 · Balance 4,010,467 F1: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Row 3 · 2022-11-12 · Other · Disposed 50,000 · Balance 3,960,467 F1: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Row 4 · 2023-02-12 · Other · Disposed 50,000 · Balance 3,910,467 F1: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Row 5 · 2023-05-12 · Other · Disposed 50,000 · Balance 3,860,467 F1: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer.
MUSTANG BIO, INC.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 536,577 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 278,385 · Balance 536,577 F1: The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 278,385 shares were granted by the Issuer to the Reporting person for the 2025 annual dividend. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 278,385 shares were granted by the Issuer to the Reporting person for the 2025 annual dividend.
NATIONAL HOLDINGS CORP
Report date September 12, 2016 · Filed September 22, 2016
Jointly reported with FBIO Acquisition, Inc., Opus Point Partners, LLC, Opus Point Healthcare Innovations (Offshore) Fund Ltd., WEISS MICHAEL S, ROSENWALD LINDSAY A MD
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,037,482 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,037,482 F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 371,584 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 371,584 F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 89,530 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 89,530 F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 44,884 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 44,884 F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 16,294 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 16,294 F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Checkpoint Therapeutics, Inc.
Report date May 29, 2025 · Filed June 03, 2025
Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-05-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-29 · Sale · Disposed 100,000 · Balance 6,122,249 F1: On July 15, 2015, pursuant to the Fortress Biotech, Inc. Long Term Incentive Plan, the Reporting Person issued warrants to purchase 500,000 shares of Issuer common stock (out of the Reporting Person's holdings in the Issuer) to each of Lindsay A. Rosenwald and Michael S. Weiss (collectively, the "Warrants"). Following a December 2022 reverse stock split by the Issuer, the Warrants became exercisable into 100,000 shares of Issuer common stock in the aggregate, with an exercise price of $1.29 per share. Dr. Rosenwald and Mr. Weiss exercised the Warrants on May 29, 2025. Row 2 · 2025-05-30 · Disposition to issuer · Disposed 6,122,249 · Balance 0 F2: On March 9, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sun Pharmaceutical Industries, Inc., a Delaware corporation ("Parent"), and Snoopy Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). On May 30, 2025 (the "Closing Date"), Merger Sub merged with and into the Issuer pursuant to the Merger Agreement, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As a result of the Merger, each issued and outstanding share of Common Stock and Class A Common Stock that was previously held by the Reporting Person was automatically canceled and ceased to exist and was converted into the right to receive: (i) $4.10 in cash, without interest, and (ii) one non-tradable contingent value right (a "CVR"), which represents the right to receive a contingent cash payment of up to $0.70 upon the achievement of a specified milestone. |
| CLASS A COMMON STOCK, PAR VALUE $0.0001SEC Table II · derivative / convertible security · Conversion / exercise price $4.10 | Direct | 0 |
Reported balance
After 2025-05-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-30 · Disposition to issuer · Disposed 700,000 · Balance 0 F2: On March 9, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sun Pharmaceutical Industries, Inc., a Delaware corporation ("Parent"), and Snoopy Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). On May 30, 2025 (the "Closing Date"), Merger Sub merged with and into the Issuer pursuant to the Merger Agreement, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As a result of the Merger, each issued and outstanding share of Common Stock and Class A Common Stock that was previously held by the Reporting Person was automatically canceled and ceased to exist and was converted into the right to receive: (i) $4.10 in cash, without interest, and (ii) one non-tradable contingent value right (a "CVR"), which represents the right to receive a contingent cash payment of up to $0.70 upon the achievement of a specified milestone. F3: Each share of Class A Common Stock had no expiration date and was convertible at any time at the option of Reporting Person into one share of the Issuer's Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 15, 2015, pursuant to the Fortress Biotech, Inc. Long Term Incentive Plan, the Reporting Person issued warrants to purchase 500,000 shares of Issuer common stock (out of the Reporting Person's holdings in the Issuer) to each of Lindsay A. Rosenwald and Michael S. Weiss (collectively, the "Warrants"). Following a December 2022 reverse stock split by the Issuer, the Warrants became exercisable into 100,000 shares of Issuer common stock in the aggregate, with an exercise price of $1.29 per share. Dr. Rosenwald and Mr. Weiss exercised the Warrants on May 29, 2025.
F2: On March 9, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sun Pharmaceutical Industries, Inc., a Delaware corporation ("Parent"), and Snoopy Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). On May 30, 2025 (the "Closing Date"), Merger Sub merged with and into the Issuer pursuant to the Merger Agreement, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As a result of the Merger, each issued and outstanding share of Common Stock and Class A Common Stock that was previously held by the Reporting Person was automatically canceled and ceased to exist and was converted into the right to receive: (i) $4.10 in cash, without interest, and (ii) one non-tradable contingent value right (a "CVR"), which represents the right to receive a contingent cash payment of up to $0.70 upon the achievement of a specified milestone.
F3: Each share of Class A Common Stock had no expiration date and was convertible at any time at the option of Reporting Person into one share of the Issuer's Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 21:30 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 278,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001429260-26-000002 · form4-01052026_040122.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,577 F1 · shares: The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 278,385 shares were granted by the Issuer to the Reporting person for the 2025 annual dividend. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:05 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 111,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001429260-26-000004 · form4-01062026_040109.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 439,733 F1 · shares: The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 111,209 shares were granted by the Issuer to the reporting Person for the 2025 annual dividend. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:05 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 59,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001429260-25-000004 · form4-10012025_041032.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,192 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the receipt of proceeds by the Issuer upon the exercise of warrants previously issued by the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 22:34 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | Disposition to issuerCLASS A COMMON STOCK, PAR VALUE $0.0001 · Derivative | 700,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001415889-25-015470 · form4-06032025_100636.xml · derivative · entry 3 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 700,000 shares Expires not disclosed F2 · derivative.exercise_date: On March 9, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sun Pharmaceutical Industries, Inc., a Delaware corporation ("Parent"), and Snoopy Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). On May 30, 2025 (the "Closing Date"), Merger Sub merged with and into the Issuer pursuant to the Merger Agreement, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As a result of the Merger, each issued and outstanding share of Common Stock and Class A Common Stock that was previously held by the Reporting Person was automatically canceled and ceased to exist and was converted into the right to receive: (i) $4.10 in cash, without interest, and (ii) one non-tradable contingent value right (a "CVR"), which represents the right to receive a contingent cash payment of up to $0.70 upon the achievement of a specified milestone. F3 · derivative.exercise_date: Each share of Class A Common Stock had no expiration date and was convertible at any time at the option of Reporting Person into one share of the Issuer's Common Stock. F2 · derivative.expiration_date: On March 9, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sun Pharmaceutical Industries, Inc., a Delaware corporation ("Parent"), and Snoopy Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). On May 30, 2025 (the "Closing Date"), Merger Sub merged with and into the Issuer pursuant to the Merger Agreement, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As a result of the Merger, each issued and outstanding share of Common Stock and Class A Common Stock that was previously held by the Reporting Person was automatically canceled and ceased to exist and was converted into the right to receive: (i) $4.10 in cash, without interest, and (ii) one non-tradable contingent value right (a "CVR"), which represents the right to receive a contingent cash payment of up to $0.70 upon the achievement of a specified milestone. F3 · derivative.expiration_date: Each share of Class A Common Stock had no expiration date and was convertible at any time at the option of Reporting Person into one share of the Issuer's Common Stock. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 22:34 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | Disposition to issuerCOMMON STOCK, PAR VALUE $0.0001 | 6,122,249 | $4.10 | $25,101,220.90 |
DisclosureSEC source: 0001415889-25-015470 · form4-06032025_100636.xml · nonDerivative · entry 2 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: On March 9, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sun Pharmaceutical Industries, Inc., a Delaware corporation ("Parent"), and Snoopy Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). On May 30, 2025 (the "Closing Date"), Merger Sub merged with and into the Issuer pursuant to the Merger Agreement, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As a result of the Merger, each issued and outstanding share of Common Stock and Class A Common Stock that was previously held by the Reporting Person was automatically canceled and ceased to exist and was converted into the right to receive: (i) $4.10 in cash, without interest, and (ii) one non-tradable contingent value right (a "CVR"), which represents the right to receive a contingent cash payment of up to $0.70 upon the achievement of a specified milestone. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 22:34 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK, PAR VALUE $0.0001 | 100,000 | $1.29 | $129,000.00 |
DisclosureSEC source: 0001415889-25-015470 · form4-06032025_100636.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,122,249 F1 · price: On July 15, 2015, pursuant to the Fortress Biotech, Inc. Long Term Incentive Plan, the Reporting Person issued warrants to purchase 500,000 shares of Issuer common stock (out of the Reporting Person's holdings in the Issuer) to each of Lindsay A. Rosenwald and Michael S. Weiss (collectively, the "Warrants"). Following a December 2022 reverse stock split by the Issuer, the Warrants became exercisable into 100,000 shares of Issuer common stock in the aggregate, with an exercise price of $1.29 per share. Dr. Rosenwald and Mr. Weiss exercised the Warrants on May 29, 2025. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:05 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 67,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009620 · form4-04022025_040407.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,858 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the receipt of proceeds by the Issuer upon the exercise of warrants previously issued by the Issuer. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:05 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 33,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009621 · form4-04022025_040409.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,524 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the receipt of proceeds by the Issuer upon the exercise of warrants previously issued by the Issuer. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 21:25 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005849 · form4-02272025_040201.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,222,249 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the receipt of proceeds by the Issuer upon the exercise of warrants previously issued by the Issuer. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:15 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 2,386,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000403 · form4-01032025_040107.xml · nonDerivative · entry 2 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,203,749 F2 · shares: The Reporting Person is entitled to an annual equity fee grant from the issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2024 annual equity fee grant. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:15 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 81,407 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000403 · form4-01032025_040107.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,816,941 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the exercise of warrants. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:15 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 146,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024182 · form4-10012024_041002.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,735,534 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing. F1 · balance_after: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:22 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 575,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-076298 · tm2418561-1_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,502,991 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 575,191 shares were granted by the Issuer to the Reporting Person following the closing of equity financings. F1 · balance_after: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 575,191 shares were granted by the Issuer to the Reporting Person following the closing of equity financings. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 20:05 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 413,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-048303 · tm2412005-1_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,547,393 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 413,507 shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 22:23 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 193,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-037986 · tm249605-2_4.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,096,278 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:29 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 419,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000859 · tm241755-3_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,927,800 F1 · shares: Effective April 3, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 66,003 shares were granted by the Issuer to the Reporting Person following the closing of equity financings. F3 · shares: The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 353,089 shares were granted by the Issuer to the Reporting Person for the 2023 annual dividend. F1 · balance_after: Effective April 3, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:27 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 2,101,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000853 · tm241755-1_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,133,886 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 415,728 shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. F2 · shares: The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 1,685,768 shares were granted by the Issuer to the Reporting Person for the 2023 annual dividend. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:28 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 158,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000856 · tm241755-2_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,902,373 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 20:16 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 80,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-103872 · tm2326953-2_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,744,239 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 13:02 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 418,410 | $0.72 | $301,255.20 |
DisclosureSEC source: 0001437749-23-025640 · rdgdoc.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,032,390 Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 17:15 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 81,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077533 · tm2320440d1_4.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,663,333 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing. Read SEC document |
| May 12, 2023 Filed May 31, 2024 22:26 UTC | Journey Medical Corp DERM · Entity 6273 | OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 5 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,860,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| April 04, 2023 Filed Apr 4, 2023 20:06 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 42,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041488 · tm2311448-1_4seq1.xml · nonDerivative · entry 2 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,581,927 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:08 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 52,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041491 · tm2311448-2_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613,980 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:06 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 35,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041488 · tm2311448-1_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,539,427 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing. Read SEC document |
| February 12, 2023 Filed May 31, 2024 22:26 UTC | Journey Medical Corp DERM · Entity 6273 | OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 4 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,910,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 23:40 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 2,807,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001929 · tm232514-1_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,630,620 F1 · shares: The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual dividend. F2 · balance_after: The total number of shares beneficially owned by the Reporting Person includes those transactions as disclosed on the table filed herewith as Exhibit 99. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:57 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 368,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001925 · tm232299-1_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,503,713 F1 · shares: The Reporting Person is entitled to an annual equity fee grant from the issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual equity fee grant. F2 · shares: Effective December 6, 2022, the Issuer effected a one-for-ten reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective December 6, 2022, the Issuer effected a one-for-ten reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3 · balance_after: The total number of shares beneficially owned by the Reporting Person includes those transactions as disclosed on the table filed herewith as Exhibit 99. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 22:49 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 231,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-000998 · tm231707-1_4seq1.xml · nonDerivative · entry 2 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,561 F2 · shares: The Reporting Person is entitled to an annual dividend on its outstanding Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual dividend. F4 · shares: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F4 · balance_after: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:49 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 90,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-000998 · tm231707-1_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,245 F1 · shares: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. F4 · shares: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F4 · balance_after: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| November 12, 2022 Filed May 31, 2024 22:26 UTC | Journey Medical Corp DERM · Entity 6273 | OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 3 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,960,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| August 12, 2022 Filed May 31, 2024 22:26 UTC | Journey Medical Corp DERM · Entity 6273 | OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 2 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,010,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| May 12, 2022 Filed May 31, 2024 22:26 UTC | Journey Medical Corp DERM · Entity 6273 | OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,060,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| March 31, 2017 Filed Jun 7, 2017 21:43 UTC | MUSTANG BIO, INC. NONE · Entity 8350 | GrantCommon Stock, $0.0001 par value | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 8 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,132,653 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| March 17, 2017 Filed Jun 7, 2017 21:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCommon Stock, $0.0001 par value | 721,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031577 · v467959_form4.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,702,705 F1 · kind: The Reporting Person is entitled to an annual equity fee grant from the Issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on March 17. These shares were granted by the Issuer to the Reporting Person for the 2017 annual equity fee grant. Read SEC document |
| March 13, 2017 Filed Jun 7, 2017 21:43 UTC | MUSTANG BIO, INC. NONE · Entity 8350 | GrantCommon Stock, $0.0001 par value | 767,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 7 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,131,053 F2 · kind: The Reporting Person is entitled to an annual dividend on its outstanding Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on March 13. These shares were granted by the Issuer to the Reporting Person for the 2017 annual dividend. Read SEC document |
| January 31, 2017 Filed Jun 7, 2017 21:43 UTC | MUSTANG BIO, INC. NONE · Entity 8350 | GrantCommon Stock, $0.0001 par value | 213,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 6 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,363,789 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| December 29, 2016 Filed Jun 7, 2017 21:43 UTC | MUSTANG BIO, INC. NONE · Entity 8350 | GrantCommon Stock, $0.0001 par value | 15,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 5 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,150,370 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| December 12, 2016 Filed Jun 7, 2017 21:43 UTC | MUSTANG BIO, INC. NONE · Entity 8350 | GrantCommon Stock, $0.0001 par value | 11,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 4 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,134,564 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| November 30, 2016 Filed Jun 7, 2017 21:43 UTC | MUSTANG BIO, INC. NONE · Entity 8350 | GrantCommon Stock, $0.0001 par value | 47,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 3 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,122,639 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| October 25, 2016 Filed Jun 7, 2017 21:43 UTC | MUSTANG BIO, INC. NONE · Entity 8350 | GrantCommon Stock, $0.0001 par value | 27,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 2 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,075,134 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| September 30, 2016 Filed Jun 7, 2017 21:43 UTC | MUSTANG BIO, INC. NONE · Entity 8350 | GrantCommon Stock, $0.0001 par value | 47,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,047,870 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.